Francis Medical Launches Pioneering Vanquish® Procedure for Prostate Ablation on the East Coast

A Groundbreaking Development in Prostate Cancer Treatment

On March 25, 2026, Francis Medical, Inc., a forward-thinking medical device company, made significant strides in prostate cancer treatment by successfully conducting the first commercial procedure using the Vanquish® Water Vapor Ablation System on the East Coast. This landmark event took place at the Chesapeake Regional Surgery Center in Virginia Beach, where Dr. Robert Given of Urology of Virginia performed the procedure on a patient diagnosed with localized prostate cancer.

The Vanquish® system represents a major evolution in minimizing invasive procedures while effectively targeting prostate tissue. Unlike traditional surgeries or radiation therapies, which can lead to serious side effects such as urinary incontinence and erectile dysfunction, the Vanquish® system employs high-energy sterile water vapor for tissue ablation, aiming to preserve a patient's quality of life.

Dr. Given expressed enthusiasm for this new technology, stating, "Introducing Vanquish marks an important milestone for both our practice and patients across the East Coast. This initial case demonstrates how seamlessly this technology can be integrated into clinical care, providing a minimally invasive option for targeted tissue ablation."

The recent FDA clearance for the Vanquish® system highlighted its potential benefits, with interim data from the ongoing VAPOR 2 pivotal study showing an impressive 91% of eligible patients achieving negative biopsy results within six months of the procedure. Furthermore, the study reported that the system is well-tolerated, with no serious adverse events linked to the device, making it a compelling choice for patients seeking pain-free alternatives.

A significant milestone was also noted at the recent European Association of Urology international scientific meeting, where data demonstrated that 93% of patients were satisfied or extremely satisfied with their treatment experience, revealing a strong belief in the efficacy of the procedure.

Francis Medical's Chief Executive Officer, Mike Kujak, reflected on this momentous occasion, stating, "We are proud to support Dr. Given and the team at Urology of Virginia as they introduce Vanquish into clinical practice. These first commercial cases on the East Coast represent an important step in expanding access to our technology..."

The mission driving Francis Medical is to evolve urological cancer treatments that balance effectiveness with patient comfort. The company was founded with a profound personal backstory. Founder Michael Hoey established this venture as a tribute to his father, Francis Hoey, who faced the challenges of prostate cancer treatments that had debilitating effects on his life.

The Vanquish® system's launch not only offers the possibility of effective localized cancer treatment but also emphasizes the importance of improving the overall experience for patients undergoing therapy. By adopting innovative methods, Francis Medical hopes to make enduring changes in how prostate cancer can be treated, ultimately leading to improved outcomes.

The company’s commitment to funding research and clinical trials will continue, with further evaluations planned to gather more long-term data that can support expanded indications for the treatment of localized prostate cancer.

As this transformative technology gains traction within clinical settings, patients and healthcare providers alike can look forward to a future where the management of prostate cancer can be safe, efficient, and patient-centered.

For more information about Francis Medical and its pioneering treatments, please visit www.francismedical.com.

Conclusion

With the first successful commercial procedure conducted, Francis Medical's Vanquish® system signals a promising change in the treatment landscape for prostate cancer. As more healthcare providers adopt this technology, the potential for improved patient outcomes becomes a reality, showcasing the imperative need for innovation in medical treatments.